Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | GCK | P35557 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.43 |
| ▸ | PDE4A | P27815 | 3/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | CPT2 | P23786 | 2/20 | 0.42 |
| ▸ | CPT1A | P50416 | 2/20 | 0.42 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | ACACA | Q13085 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30517690 | 1.00 | EPHX2 (0.50) | EPHX2POLBGRIK1GRIA2AKR1C3 | |
| SCHEMBL30567543 | 1.00 | EPHX2 (0.50) | EPHX2POLBGRIK1GRIA2AKR1C3 | |
| SCHEMBL29267960 | 1.00 | EPHX2 (0.50) | EPHX2POLBGRIK1GRIA2AKR1C3 | |
| SCHEMBL1168318 | 0.91 | EPHX2 (0.55) | EPHX2POLBGRIK1GRIA2AKR1C3 | |
| SCHEMBL30507908 | 0.91 | EPHX2 (0.55) | EPHX2POLBGRIK1GRIA2AKR1C3 | |
| SCHEMBL29440998 | 0.88 | AKR1C3 (0.53) | EPHX2GRIK1GRIA2AKR1C3OPRK1 | |
| SCHEMBL1377451 | 0.87 | OPRK1 (0.57) | OPRK1 | |
| SCHEMBL30567549 | 0.87 | OPRK1 (0.57) | OPRK1 | |
| SCHEMBL29505911 | 0.83 | EPHX2 (0.65) | EPHX2GRIK1GRIA2AKR1C3PDE4D | |
| SCHEMBL28885485 | 0.83 | POLB (0.45) | POLBPDE4DPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022146698-A1 | SOS1 INHIBITORS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2022-07-07 | — | — | WO | disclosed |
| US-6956037-B2 | Benzamide derivatives for the treatment of diseases mediated by cytokines | ASTRAZENECA AB (SE) | 2005-10-18 | — | — | US | disclosed |
| EP-1077931-B1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 2004-11-17 | — | — | EP | disclosed |
| US-20030212068-A1 | Benzamide derivatives for the treatment of diseases mediated by cytokines | ASTRAZENECA AB | 2003-11-13 | — | — | US | disclosed |
| US-6579872-B1 | Such as TNF, in particular of TNF alpha, and various interleukins, in particular IL-1; N-(5-(4-(3-hydroxypropoxy)benzamido)-2-methylphenyl)-3,4-dimethoxybenzamide | ASTRAZENECA AB (SE) | 2003-06-17 | — | — | US | disclosed |
| EP-1077931-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | AstraZeneca AB (SE) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059959-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212068-A1 | Benzamide derivatives for the treatment of diseases mediated by cytokines | IL2, IL6, IL6ST | EPHX2 1236/4885POLB 2378/4885GRIK1 3715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.